FTC’s Stern POM Opinion Expands Disease Claim Findings
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission’s 5-0 decision against POM Wonderful finds the firm made false and misleading claims and requires it to conduct at least two randomized controlled clinical trials for all future disease-related claims. POM vows to appeal the order in federal court.
You may also be interested in...
Supplement Firms Agree To Leave Market After Being Released From FTC Contempt Complaint
FTC announces Health Research Laboratories, Whole Body Supplements and their owner, Kramer Duhon, agree to settlement in administrative proceeding opened in November 2020 after federal judge dismissed contempt complaint from 2018 settlement.
Supreme Court Slays POM Wonderful's Appeal Of FTC Order
The high court denies the firm's writ of certiorari to review an appellate 2015 ruling largely upholding a 2013 FTC order on claims made for POM Wonderful 100% Pomegranate Juice and POMx pills and liquid supplements.
FTC Homeopathic Meeting Features Tort Attorney, Commissioner Critical Of Enforcement
The event agenda includes eight industry executives, researchers, attorneys and FDA officials who made presentations or were agency panel members at FDA’s public hearing in April. Commissioner Maureen Ohlhausen, who has advocated allowing firms regulatory room to advertise, speaks to open the meeting.